Published in Cancer on November 15, 1998
Novel Imaging Techniques in Barrett's Esophagus | NCT00576498
Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer | NCT01704690
The Study of Barrett's Esophagus: What Are the Factors of Progression (BEST) | NCT00586404
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet (2009) 26.09
Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst (2008) 6.00
Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut (2001) 4.97
Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila) (2008) 3.97
Gastric adenocarcinoma: review and considerations for future directions. Ann Surg (2005) 3.83
Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol (2006) 3.28
Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut (2004) 3.26
ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol (2015) 3.22
Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol (2000) 2.99
MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg (2007) 2.85
Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg (2000) 2.85
Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg (2001) 2.49
Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg (2007) 2.48
Increasing incidence of Barrett's oesophagus in the general population. Gut (2005) 2.34
Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer (2009) 2.33
Identifying intestinal metaplasia at the squamocolumnar junction by using optical coherence tomography. Gastrointest Endosc (2006) 2.31
Abdominal obesity, ethnicity and gastro-oesophageal reflux symptoms. Gut (2006) 2.28
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol (2001) 2.17
Does obesity affect outcomes in patients undergoing esophagectomy for cancer? A meta-analysis. World J Surg (2012) 2.11
Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut (2008) 2.08
Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut (2001) 2.05
Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy. Ann Surg (2000) 1.98
Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut (2002) 1.92
Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev (2008) 1.89
Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology (2008) 1.87
Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut (2002) 1.84
Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol (2010) 1.84
Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. Gut (2003) 1.81
Characterization of buried glands before and after radiofrequency ablation by using 3-dimensional optical coherence tomography (with videos). Gastrointest Endosc (2012) 1.80
Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil (2011) 1.79
Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut (2005) 1.74
Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin Gastroenterol Hepatol (2009) 1.74
Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev (2014) 1.73
A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut (2001) 1.72
Body mass index and Barrett's oesophagus in women. Gut (2009) 1.70
Effect of pyloric drainage procedures on gastric passage and bile reflux after esophagectomy with gastric conduit reconstruction. Langenbecks Arch Surg (2007) 1.67
Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut (2006) 1.67
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
Predictive factors for surgical complications of laparoscopy-assisted distal gastrectomy for gastric cancer. Surg Endosc (2008) 1.64
Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst (2010) 1.60
Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut (2006) 1.58
Changes of Esophagogastric Junctional Adenocarcinoma and Gastroesophageal Reflux Disease Among Surgical Patients During 1988-2012: A Single-institution, High-volume Experience in China. Ann Surg (2016) 1.57
Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut (2002) 1.57
Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut (2007) 1.57
Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol (2012) 1.53
MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol (2009) 1.51
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer (2002) 1.49
Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction. World J Surg (2010) 1.48
Microbiome and malignancy. Cell Host Microbe (2011) 1.45
Antireflux surgery, barrett esophagus, and adenocarcinoma: there is still room for doubt. Ann Surg (2007) 1.44
Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology (2011) 1.44
Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst (1999) 1.44
Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut (2006) 1.42
Comparative acceptability of transnasal esophagoscopy and esophageal capsule esophagoscopy: a randomized, controlled trial in veterans. Gastrointest Endosc (2014) 1.41
Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc (2005) 1.37
Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer (2010) 1.36
Epidemiology of gastroesophageal reflux disease: a general population-based study in Xi'an of Northwest China. World J Gastroenterol (2004) 1.36
Risk factors for esophageal and gastric cancers in Shanxi Province, China: a case-control study. Cancer Epidemiol (2011) 1.35
MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res (2009) 1.35
Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut (2001) 1.34
The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther (2012) 1.33
Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer (2008) 1.32
Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol Cancer (2005) 1.32
Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev (2009) 1.30
Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol (2012) 1.30
Investigation and management of chronic dysphagia. BMJ (2003) 1.30
Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res (2009) 1.30
What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut (2004) 1.29
Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia (2006) 1.28
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther (2011) 1.26
Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol (2011) 1.25
Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. J Proteome Res (2009) 1.25
Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer (2014) 1.25
Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Cancer Causes Control (2008) 1.25
Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates. Ann Surg (2006) 1.24
Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins. Gastroenterology (2006) 1.22
Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology (2015) 1.21
Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center. World J Surg (2009) 1.20
Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol (2010) 1.20
Identifying cancer biomarkers by mass spectrometry-based glycomics. Electrophoresis (2012) 1.19
Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study. BMC Cancer (2012) 1.19
Psychosocial working conditions and the risk of esophageal and gastric cardia cancers. Eur J Epidemiol (2004) 1.18
Food group intake and risk of subtypes of esophageal and gastric cancer. Int J Cancer (2008) 1.17
Gastric cancer: an infectious disease. Infect Dis Clin North Am (2010) 1.17
Molecular biology of Barrett's adenocarcinoma. Ann Surg (2001) 1.17
Assessment of familiality, obesity, and other risk factors for early age of cancer diagnosis in adenocarcinomas of the esophagus and gastroesophageal junction. Am J Gastroenterol (2009) 1.17
Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach. World J Surg (2006) 1.17
Patient-centered, comparative effectiveness of esophageal cancer screening: protocol for a comparative effectiveness research study to inform guidelines for evidence-based approach to screening and surveillance endoscopy. BMC Health Serv Res (2012) 1.15
Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg (2008) 1.15
Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study. Am J Gastroenterol (2009) 1.14
Screening for oesophageal cancer. Nat Rev Clin Oncol (2012) 1.13
A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Hum Pathol (2008) 1.12
Metabolic syndrome and gastrointestinal diseases. J Gastroenterol (2007) 1.12
Frozen section analysis of esophageal endoscopic mucosal resection specimens in the real-time management of Barrett's esophagus. Clin Gastroenterol Hepatol (2006) 1.12
A Large-scale genetic association study of esophageal adenocarcinoma risk. Carcinogenesis (2010) 1.12
Barrett's esophagus and the increasing role of endoluminal therapy. Therap Adv Gastroenterol (2008) 1.11
Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer (2007) 1.11
Clinicopathological Characteristics and Prognostic Factors of Patients with Siewert Type II Esophagogastric Junction Carcinoma: A Retrospective Multicenter Study. World J Surg (2016) 1.10
Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc (2002) 1.09
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA (1991) 11.53
Rising incidence of renal cell cancer in the United States. JAMA (1999) 9.57
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature (2000) 8.96
Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res (1988) 7.30
Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med (1969) 6.54
A cancer family syndrome in twenty-four kindreds. Cancer Res (1988) 6.39
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (1999) 5.09
The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med (1996) 4.81
Solid cancers after bone marrow transplantation. N Engl J Med (1997) 4.62
Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst (1993) 4.59
Snuff dipping and oral cancer among women in the southern United States. N Engl J Med (1981) 4.33
Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (1997) 4.09
Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med (2000) 3.72
Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (1998) 3.66
Agricultural herbicide use and risk of lymphoma and soft-tissue sarcoma. JAMA (1986) 3.63
Risk of cancer in renal-transplant recipients. Lancet (1973) 3.36
Risk of connective tissue disease and related disorders among women with breast implants: a nation-wide retrospective cohort study in Sweden. BMJ (1998) 3.34
Cancer risk in users of calcium channel blockers. Hypertension (1997) 3.30
Acetaminophen, aspirin, and chronic renal failure. N Engl J Med (2001) 3.28
Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst (1996) 3.26
An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res (1998) 3.22
A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control (2001) 3.13
Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet (1977) 3.05
Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA (1997) 3.00
Clues to cancer etiology from studies of farmers. Scand J Work Environ Health (1992) 2.98
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst (1996) 2.78
Recent cancer trends in the United States. J Natl Cancer Inst (1995) 2.76
Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA (1993) 2.71
The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA (1995) 2.68
Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer (1999) 2.66
Population attributable risk of renal cell cancer in Minnesota. Am J Epidemiol (1998) 2.65
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
A population-based case-control study of childhood leukemia in Shanghai. Cancer (1988) 2.59
Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA (1998) 2.55
Arsenic and respiratory cancer in man: an occupational study. J Natl Cancer Inst (1969) 2.50
International trends and patterns of primary liver cancer. Int J Cancer (2001) 2.50
Reliability of surrogate information on cigarette smoking by type of informant. Am J Epidemiol (1987) 2.49
Tobacco use and prostate cancer: 26-year follow-up of US veterans. Am J Epidemiol (1991) 2.49
Geographic patterns of lung cancer: industrial correlations. Am J Epidemiol (1976) 2.45
Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer (2003) 2.43
Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (1998) 2.43
Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev (2002) 2.36
Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst (2000) 2.32
Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol (2001) 2.30
Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst (1969) 2.30
Declining lung cancer rates among young men and women in the United States: a cohort analysis. J Natl Cancer Inst (1989) 2.28
Cancer mortality among chemists. J Natl Cancer Inst (1969) 2.28
Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res (1990) 2.21
Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med (1977) 2.20
Fluoridated drinking water and the occurrence of cancer. J Natl Cancer Inst (1976) 2.19
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol (2000) 2.18
A population--based case--control study of renal cell carcinoma. J Natl Cancer Inst (1984) 2.17
Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst (1998) 2.13
Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (2001) 2.13
Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers. J Natl Cancer Inst (1997) 2.12
Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst (1987) 2.12
Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst (1976) 2.11
Risk factors for esophageal cancer in Shanghai, China. I. Role of cigarette smoking and alcohol drinking. Int J Cancer (1994) 2.09
Patterns of lung cancer risk according to type of cigarette smoked. Int J Cancer (1984) 2.07
Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst (1997) 2.06
Synthetic sweetener consumption and bladder cancer trends in the United States. Nature (1970) 2.05
The influence of cigarette smoking, alcohol, and green tea consumption on the risk of carcinoma of the cardia and distal stomach in Shanghai, China. Cancer (1996) 2.05
Geographic patterns of oral cancer in the United States: etilogic implications. J Chronic Dis (1977) 2.02
Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst (1987) 2.02
Solid tumors after chronic lymphocytic leukemia. Blood (2001) 2.01
Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst (1987) 2.01
Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control (2000) 2.00
Passive smoking and lung cancer. J Natl Cancer Inst (1986) 1.99
Smoking, air pollution, and the high rates of lung cancer in Shenyang, China. J Natl Cancer Inst (1989) 1.99
A population-based case-control study of thyroid cancer. J Natl Cancer Inst (1987) 1.98
Epidemiology of uterine cervical cancer. J Chronic Dis (1986) 1.97
Epidemiology of human leukemia: recent observations. J Natl Cancer Inst (1967) 1.97
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev (2001) 1.95
Indoor radon and lung cancer in China. J Natl Cancer Inst (1990) 1.95
Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. J Natl Cancer Inst (1998) 1.91
Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res (1991) 1.89
A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer (2003) 1.88
Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer (2007) 1.87
Assessment of lung cancer risk factors by histologic category. J Natl Cancer Inst (1984) 1.84